| dbo:abstract
|
- إكرومكسيماب هو جسم مضاد وحيد النسيلة طورته لعلاج الورم الميلانيني الخبيث. (ar)
- Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma. The drug was developed by , Ltd. As of December 2015 development had been discontinued. (en)
- L'ecromeximab è un anticorpo monoclonale di tipo chimerico sviluppato per il trattamento del melanoma maligno. Questo farmaco è stato sviluppato dalla Kyōwa Hakko Kogyo Co. , Ltd. Il farmaco agisce sull'antigene GD3 ganglioside. (it)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 1974 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:mabType
| |
| dbp:molecularWeight
| |
| dbp:source
| |
| dbp:target
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- إكرومكسيماب هو جسم مضاد وحيد النسيلة طورته لعلاج الورم الميلانيني الخبيث. (ar)
- Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma. The drug was developed by , Ltd. As of December 2015 development had been discontinued. (en)
- L'ecromeximab è un anticorpo monoclonale di tipo chimerico sviluppato per il trattamento del melanoma maligno. Questo farmaco è stato sviluppato dalla Kyōwa Hakko Kogyo Co. , Ltd. Il farmaco agisce sull'antigene GD3 ganglioside. (it)
|
| rdfs:label
|
- إكرومكسيماب (ar)
- Ecromeximab (en)
- Ecromeximab (it)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
